| Literature DB >> 27824933 |
Jinzhu Huang1, Xiaofang Wang2, Xiaohong Chen3, Qiuyue Song4, Wen Liu1, Laichun Lu5.
Abstract
BACKGROUND: Post-operative endophthalmitis is a rare and dreaded complication in ophthalmic operations because it often induces irreparable vision loss. Although many ophthalmological studies aimed at reducing the rate of endophthalmitis have been performed around the world, controversy continues to surround some issues, including the choice of antimicrobials and their route of administration, duration and timing. The aim of this study is to investigate some of these unresolved issues.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27824933 PMCID: PMC5100907 DOI: 10.1371/journal.pone.0166141
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram showing the selection process used to include studies in the meta-analysis.
Main characteristics of the studies included in the meta-analysis.
| Rush,2015 | 71.0 | 49.4 | CAS | COS | 3 months | 9386 | 11333 | IC vancomycin, PVI | PVI | PE | PE | RPE | High |
| Anijeet,2010 | NA | NA | CAS | COS | 6 weeks | 12702 | 3904 | IC vancomycin, PVI | PVI | PE | PE | RPE | Moderate |
| Rudnisky,2014 | NA | NA | CAS | CCS | 6 weeks | 11818 | 59739 | IC vancomycin | No intracameral antibiotic | PE | PE | RPE | Moderate |
| Rudnisky,2014 | NA | NA | CAS | CCS | 6 weeks | 3738 | 59739 | IC moxifloxacin | No intracameral antibiotic | PE | PE | RPE | Moderate |
| Shorstein,2013 | 74.0 | NA | CAS | CCS | 12 months | 1890 | 3655 | IC moxifloxacin, PVI | PVI | PE | PE | RPE | Moderate |
| Haripriya,2016 | NA | NA | CAS | COS | 6 weeks | 38160 | 78554 | IC moxifloxacin, PVI | PVI | PE | PE | RPE | High |
| Matsuura,2013 | NA | NA | CAS | COS | 1 month | 18794 | 15958 | IC moxifloxacin, PVI | PVI | PE | PE | RPE | Moderate |
| Friling,2013a | NA | 38.3 | CAS | COS | 10 months | 6897 | 2804 | IC moxifloxacin, PVI | PVI | PE | PE | RPE | High |
| Galvis,2014 | 67.2 | NA | CAS | COS | 2 weeks | 1618 | 1056 | IC moxifloxacin, PVI | PVI | PE | PE | RPE | Moderate |
| Jabbarvand,2016b | 79.0 | NA | CAS | RCS | 6 weeks | 69120 | 25290 | SI antibiotic +PVI | IC+PVI | PE | PE | RPE | Moderate |
| Jabbarvand,2016c | 79.0 | NA | CAS | RCS | 6 weeks | 69120 | 76800 | SI antibiotic +PVI | topical antibiotic +PVI | PE | PE | RPE | Moderate |
| Jabbarvand,2016d | 79.0 | NA | CAS | RCS | 6 weeks | 69120 | 260744 | SI antibiotic +PVI | PVI | PE | PE | RPE | Moderate |
| Asencio,2015 | 71.5 | NA | CAS | CCS | 6 weeks | 5068 | 9217 | SI gentamicin +PVI | Irrigation BBS+ vancomycin+ gentamicin +PVI | PE | PE | RPE | High |
| Tan,2012 | NA | NA | CAS | COS | 1 month | 29539 | 20638 | SI gentamicin+ cefazolin +PVI | IC cefazolin +PVI | PE | PE | RPE | Moderate |
| Yu-Wai,2008 | NA | NA | CAS | COS | 3 weeks | 19425 | 17318 | SI cefuroxime +PVI | IC cefuroxime +PVI | PE | PE | RPE | Moderate |
| Colleaux,2000b | NA | NA | CAS | COS | NA | 8856 | 5030 | SI gentamicin ± cefazolin | PVI +Topical antibiotic | PE | PE | RPE | Moderate |
| ESCRS,2007a | NA | NA | CAS | RCT | 6 weeks | 4000 | 3997 | Topical levofloxacin +IC cefuroxime +PVI | Placebo +IC cefuroxime +PVI | PE | PE | RPE | High |
| ESCRS,2007b | NA | NA | CAS | RCT | 6 weeks | 3984 | 3990 | Topical levofloxacin +PVI | Placebo +PVI | PE | PE | RPE | High |
| Coskun,2011a | NA | 51.2 | CAS | RCT | NA | 54 | 53 | Topical ciprofloxacin | PVI | PE | PE | MIR | Moderate |
| Coskun,2011b | NA | 51.2 | CAS | RCT | NA | 57 | 53 | Topical ofloxacin | PVI | PE | PE | MIR | Moderate |
| Eyal,2009 | 69.7 | 48.9 | OCS | RCT | 72 hours | 237 | 227 | Topical moxifloxacin +PVI | PVI | PE | PE | MIR | Moderate |
| Kaspar,2008 | 67.8 | 34.1 | OCS | RCT | 10 days | 67 | 65 | Topical levofloxacin +PVI | PVI | PE | PE | MIR | High |
| Colleaux,2000a | NA | NA | CAS | COS | NA | 12152 | 1734 | Topical Tobramycin or Gentamicin or Ofloxacin or Polymyxin-trimethoprim | SI antibiotic +PVI | PE | PE | RPE | Moderate |
| Friling,2013b | NA | NA | CAS | COS | 10 months | 7307 | 396894 | Topical chloramphenicol or fusidic acid | IC antibiotic +PVI | PE | PE | RPE | High |
| Jabbarvand,2016a | 79.0 | NA | CAS | RCS | 6 weeks | 76800 | 260744 | Topical ciprofloxacin +PVI | PVI | PE | PE | RPE | Moderate |
| Bing,2015 | 70.6 | 50.4 | CAS | RCT | 5 days | 69 | 64 | Topical neomycin/polymyxin-B | Topical neomycin/polymyxin-B | 1d | 1h | MIR | Moderate |
| Inoue,2008a | 74.0 | 46.3 | CAS | RCT | 5 days | 79 | 76 | Topical levofloxacin | Topical levofloxacin | 3d | 1h | MIR | Moderate |
| Inoue,2008b | 74.0 | 46.3 | CAS | RCT | 5 days | 79 | 89 | Topical levofloxacin | Topical levofloxacin | 3d | 1d | MIR | Moderate |
| Inoue,2008c | 74.0 | 46.3 | CAS | RCT | 5 days | 89 | 76 | Topical levofloxacin | Topical levofloxacin | 1d | 1h | MIR | Moderate |
| Lingmin,2009 | 71.1 | 50.8 | OCS | RCT | 10 days | 57 | 63 | Topical moxifloxacin | Topical moxifloxacin | 3d | 1d | MIR | Moderate |
| Ta,2002 | NA | NA | CAS | RCT | 10 days | 43 | 48 | Topical ofloxacin | Topical ofloxacin | 3d | 1h | MIR | High |
| Ta,2007 | NA | NA | CAS | RCT | 6 days | 50 | 50 | Topical levofloxacin | Topical levofloxacin | 3d | 1d | MIR | High |
| Christopher,2008 | 69.3 | 68.3 | OCS | COS | 5 days | 60 | 60 | Topical moxifloxacin | Topical moxifloxacin | 1d | 1h | MIR | Moderate |
| Jason,2008 | 67.7 | 58.3 | OCS | COS | 5 days | 60 | 60 | Topical gatifloxacin | Topical gatifloxacin | 1d | 1h | MIR | Moderate |
Footnotes:Age: Mean age or median age.
Abbreviations: NA = not available, T = treatment group, C = control group, CAS = cataract surgery, OCS = ocular surgery, COS = cohort study, CCS = case-control study, RCT = randomized controlled trial, RCS = retrospective cross-section study, IC = intracameral, SI = subconjunctival injection, PVI = povidone-iodine, PE = perioperation, 1d = 1 day before surgery, 3d = 3 days before surgery, 1h = within 1 hour before surgery, RPE = rate of postoperative endophthalmitis, MIR = microbial isolation rate.
Fig 2Forest plot of the Rate of Postoperative Endophthalmitis (A: the effect of including and not including Intracameral Antibiotics; B: the effect of using VS not using subconjunctival antibiotic injections; C: the effect of using VS not using Topical Antibiotics). The vertical line indicates no difference between the groups. RRs are represented by diamond shapes, and 95% CIs are depicted by horizontal lines. Squares indicate point estimates, and the size of each square indicates the weight of the given study in the meta-analysis. M-H, Mantel-Haenszel random-effects model.
Fig 3Forest plot of the Microbial Isolation Rate (A: the effect of using VS not using Topical Antibiotics; B: the effect of Long-term VS Short-term use). The vertical line indicates no difference between the groups. RRs are represented by diamond shapes, and 95% CIs are depicted by horizontal lines. Squares indicate point estimates, and the size of each square indicates the weight of the given study in the meta-analysis. M-H, Mantel-Haenszel random-effects model.